{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:37:40Z","timestamp":1789709860416,"version":"4.0.1"},"reference-count":298,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The JAK-STAT signaling pathway (Janus Kinase-Signal Transducer and Activator of Transcription) is a crucial molecular cascade that regulates immune responses, cell proliferation, and hematopoiesis. Germline or somatic mutations affecting this pathway leads to a wide range of pathologies, from severe immunodeficiencies to inflammatory and autoimmune diseases, as well as hematologic malignancies. Loss-of-function mutations impair cytokine signaling and primarily result in immunodeficiency, while gain-of-function mutations cause excessive pathway activation, promoting autoimmune diseases and myeloproliferative syndromes. Advances in our understanding of the JAK-STAT pathway and its involvement in various diseases have opened new perspectives in precision medicine and targeted therapies including JAK inhibitors (JAKi), gene therapy, and hematopoietic stem cell transplantation (HSCT). A detailed understanding of specific mutations and their effects on intracellular signaling allows for the refinement of therapeutic strategies and optimization of patient management. In this review, we examined the biology of the JAK-STAT pathway, highlighted the key pathogenic mutations and their clinical consequences, and described the laboratory and diagnostic approaches used to investigate this pathway.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1669688","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:29:37Z","timestamp":1765175377000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["JAK\/STAT in human diseases: a common axis in immunodeficiencies and hematological disorders"],"prefix":"10.3389","volume":"16","author":[{"given":"Reda","family":"Djidjik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Lamara Mahammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilya Meriem","family":"Berkani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Allam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa Hamidou","family":"Benmoussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merzak","family":"Gharnaout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brahim","family":"Belaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16305","DOI":"10.1126\/science.277.5332.1630","article-title":"STATs and gene regulation","volume":"277","author":"Darnell","year":"1997","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5914","DOI":"10.1038\/377591a0","article-title":"Cytokine receptor signalling","volume":"377","author":"Ihle","year":"1995","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"54758","DOI":"10.4049\/jimmunol.1102913","article-title":"Cytokine signaling: birth of a pathway","volume":"187","author":"O\u2019Shea","year":"2011","journal-title":"J Immunol Baltim Md 1950"},{"key":"B4","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.3390\/cancers11122002","article-title":"JAK-STAT signaling: A double-edged sword of immune regulation and cancer progression","volume":"11","author":"Owen","year":"2019","journal-title":"Cancers"},{"key":"B6","doi-asserted-by":"publisher","first-page":"19842009","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci Publ Protein Soc"},{"key":"B7","doi-asserted-by":"publisher","first-page":"31322","DOI":"10.1016\/0092-8674(92)90105-L","article-title":"A protein tyrosine kinase in the interferon alpha\/beta signaling pathway","volume":"70","author":"Velazquez","year":"1992","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s40425-018-0436-5","article-title":"STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial","volume":"6","author":"Reilley","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13045-021-01214-y","article-title":"STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer","volume":"14","author":"Awasthi","year":"2021","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2301\u221218","DOI":"10.1016\/j.ajhg.2021.10.007","article-title":"Identification of discriminative gene-level and protein-level features associated with pathogenic gain-of-function and loss-of-function variants","volume":"108","author":"Sevim Bayrak","year":"2021","journal-title":"Am J Hum Genet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1038\/s41467-022-31686-6","article-title":"Loss-of-function, gain-of-function and dominant-negative mutations have profoundly different effects on protein structure","volume":"13","author":"Gerasimavicius","year":"2022","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","first-page":"35767","DOI":"10.1016\/j.jaci.2024.09.020","article-title":"JAK-STAT signaling pathway, immunodeficiency, inflammation, immune dysregulation, and inborn errors of immunity","volume":"155","author":"Samra","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"132659","DOI":"10.1007\/s10875-023-01483-x","article-title":"JAKs and STATs from a clinical perspective: loss-of-function mutations, gain-of-function mutations, and their multidimensional consequences","volume":"43","author":"Ott","year":"2023","journal-title":"J Clin Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.70962\/jhi.20250002","article-title":"The 2024 update of IUIS phenotypic classification of human inborn errors of immunity","volume":"1","author":"Bousfiha","year":"2025","journal-title":"J Hum Immun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.4049\/jimmunol.1401867","article-title":"Mechanisms of Jak\/STAT signaling in immunity and disease","volume":"194","author":"Villarino","year":"2015","journal-title":"J Immunol Baltim Md 1950"},{"key":"B16","doi-asserted-by":"publisher","first-page":"177990","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"104052","DOI":"10.1182\/blood.2019000553","article-title":"Overexpression of wild-type IL-7R\u03b1 promotes T-cell acute lymphoblastic leukemia\/lymphoma","volume":"138","author":"Silva","year":"2021","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2465551","article-title":"CALR-mutated myeloproliferative neoplasms","volume":"66","author":"Bellani","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"B19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12943-023-01929-1","article-title":"JAK\/STAT in leukemia: a clinical update","volume":"23","author":"Liang","year":"2024","journal-title":"Mol Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"91125","DOI":"10.1016\/j.jaci.2021.08.004","article-title":"JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition","volume":"148","author":"Luo","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"27387","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"B22","doi-asserted-by":"publisher","first-page":"36998","DOI":"10.1146\/annurev.iy.13.040195.002101","article-title":"Signaling through the hematopoietic cytokine receptors","volume":"13","author":"Ihle","year":"1995","journal-title":"Annu Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"63748","DOI":"10.1073\/pnas.91.14.6374","article-title":"Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes","volume":"91","author":"Kawamura","year":"1994","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B24","doi-asserted-by":"publisher","first-page":"23145","DOI":"10.1007\/s00005-007-0030-x","article-title":"Regulation of T cell homeostasis by JAKs and STATs","volume":"55","author":"Ross","year":"2007","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"142531","DOI":"10.1084\/jem.181.4.1425","article-title":"Regulation of JAK3 expression in human monocytes: phosphorylation in response to interleukins 2, 4, and 7","volume":"181","author":"Musso","year":"1995","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"138505","DOI":"10.1073\/pnas.94.25.13850","article-title":"Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic\u2009activity","volume":"94","author":"Zhou","year":"1997","journal-title":"Proc Natl Acad Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2497501","DOI":"10.1128\/MCB.17.5.2497","article-title":"Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop","volume":"17","author":"Feng","year":"1997","journal-title":"Mol Cell Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"20494500","DOI":"10.1074\/jbc.271.34.20494","article-title":"Interferon-alpha-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase","volume":"271","author":"Gauzzi","year":"1996","journal-title":"J Biol Chem"},{"key":"B29","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S0003-9861(02)00637-9","article-title":"Mechanism of Janus kinase 3-catalyzed phosphorylation of a Janus kinase 1 activation loop peptide","volume":"410","author":"Wang","year":"2003","journal-title":"Arch Biochem Biophys"},{"key":"B30","doi-asserted-by":"publisher","first-page":"227182","DOI":"10.1128\/MCB.01789-07","article-title":"Phosphorylation of human Jak3 at tyrosines 904 and 939 positively regulates its activity","volume":"28","author":"Cheng","year":"2008","journal-title":"Mol Cell Biol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"106276","DOI":"10.1210\/me.2009-0355","article-title":"Tyrosines 868, 966, and 972 in the kinase domain of JAK2 are autophosphorylated and required for maximal JAK2 kinase activity","volume":"24","author":"Argetsinger","year":"2010","journal-title":"Mol Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"19952001","DOI":"10.1016\/j.cellsig.2008.07.008","article-title":"Negative regulation of Jak2 by its auto-phosphorylation at tyrosine 913 via the Epo signaling pathway","volume":"20","author":"Funakoshi-Tago","year":"2008","journal-title":"Cell Signal"},{"key":"B33","doi-asserted-by":"publisher","first-page":"227081","DOI":"10.1210\/me.2007-0111","article-title":"SH2B1 enhances leptin signaling by both janus kinase 2 tyr813 phosphorylation-dependent and -independent mechanisms","volume":"21","author":"Li","year":"2007","journal-title":"Mol Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"455770","DOI":"10.1128\/MCB.24.10.4557-4570.2004","article-title":"Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B beta","volume":"24","author":"Kurzer","year":"2004","journal-title":"Mol Cell Biol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"336778","DOI":"10.1128\/MCB.00278-09","article-title":"Regulation of jak2 function by phosphorylation of tyr317 and tyr637 during cytokine signaling","volume":"29","author":"Robertson","year":"2009","journal-title":"Mol Cell Biol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"405262","DOI":"10.1128\/MCB.01591-05","article-title":"Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growthHormone and epidermal growth factor","volume":"26","author":"Mazurkiewicz-Munoz","year":"2006","journal-title":"Mol Cell Biol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"358291","DOI":"10.1074\/jbc.M109.053843","article-title":"Protein phosphatase 2A regulates interleukin-2 receptor complex formation and JAK3\/STAT5 activation","volume":"285","author":"Ross","year":"2010","journal-title":"J Biol Chem"},{"key":"B38","doi-asserted-by":"publisher","first-page":"95969","DOI":"10.1016\/S1097-2765(01)00398-7","article-title":"Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases","volume":"8","author":"Zhou","year":"2001","journal-title":"Mol Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"154958","DOI":"10.1093\/emboj\/18.6.1549","article-title":"Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain","volume":"18","author":"Cacalano","year":"1999","journal-title":"EMBO J"},{"key":"B40","doi-asserted-by":"publisher","first-page":"476372","DOI":"10.1038\/sj.emboj.7601365","article-title":"Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2","volume":"25","author":"Funakoshi-Tago","year":"2006","journal-title":"EMBO J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"180615","DOI":"10.1016\/j.cellsig.2011.06.015","article-title":"Phosphorylation of Y372 is critical for Jak2 tyrosine kinase activation","volume":"23","author":"Sayyah","year":"2011","journal-title":"Cell Signal"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1006\/geno.1995.1235","article-title":"Distribution of the mammalian Stat gene family in mouse chromosomes","volume":"29","author":"Copeland","year":"1995","journal-title":"Genomics"},{"key":"B43","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1007\/978-94-017-3000-6_2","article-title":"The STAT protein family","volume-title":"Signal transducers and activators of transcription (STATs): activation and biology","author":"Heim","year":"2003"},{"key":"B44","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0378-1119(02)00398-0","article-title":"Signaling through the JAK\/STAT pathway, recent advances and future challenges","volume":"285","author":"Kisseleva","year":"2002","journal-title":"Gene"},{"key":"B45","doi-asserted-by":"publisher","first-page":"53650","DOI":"10.1039\/b606246f","article-title":"Structure, function, and regulation of STAT proteins","volume":"2","author":"Lim","year":"2006","journal-title":"Mol Biosyst"},{"key":"B46","doi-asserted-by":"publisher","first-page":"104852","DOI":"10.1126\/science.279.5353.1048","article-title":"Structure of the amino-terminal protein interaction domain of STAT-4","volume":"279","author":"Vinkemeier","year":"1998","journal-title":"Science"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2804956","DOI":"10.1074\/jbc.273.43.28049","article-title":"Amino-terminal signal transducer and activator of transcription (STAT) domains regulate nuclear translocation and STAT deactivation","volume":"273","author":"Strehlow","year":"1998","journal-title":"J Biol Chem"},{"key":"B48","doi-asserted-by":"publisher","first-page":"307784","DOI":"10.1242\/dev.00535","article-title":"Novel level of signalling control in the JAK\/STAT pathway revealed by in situ visualisation of protein-protein interaction during Drosophila development","volume":"130","author":"Brown","year":"2003","journal-title":"Dev Camb Engl"},{"key":"B49","doi-asserted-by":"publisher","first-page":"683644","DOI":"10.1093\/emboj\/20.23.6836","article-title":"Functional interaction of STAT5 and nuclear receptor co-repressor SMRT: implications in negative regulation of STAT5-dependent transcription","volume":"20","author":"Nakajima","year":"2001","journal-title":"EMBO J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"12130","DOI":"10.1016\/S0092-8674(00)80965-4","article-title":"Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling","volume":"96","author":"Zhu","year":"1999","journal-title":"Cell"},{"key":"B51","doi-asserted-by":"publisher","first-page":"65162","DOI":"10.1038\/nrm909","article-title":"Stats: transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"98494","DOI":"10.1101\/gad.9.8.984","article-title":"A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain","volume":"9","author":"Horvath","year":"1995","journal-title":"Genes Dev"},{"key":"B53","doi-asserted-by":"publisher","first-page":"12134","DOI":"10.1089\/jir.1997.17.121","article-title":"GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression","volume":"17","author":"Decker","year":"1997","journal-title":"J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"510612","DOI":"10.1128\/MCB.19.7.5106","article-title":"The linker domain of stat1 is required for gamma interferon-driven transcription","volume":"19","author":"Yang","year":"1999","journal-title":"Mol Cell Biol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"28997","DOI":"10.1042\/bj20030708","article-title":"Analysis of Stat3 (signal transducer and activator of transcription 3) dimerization by fluorescence resonance energy transfer in living cells","volume":"377","author":"Kretzschmar","year":"2004","journal-title":"Biochem J"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.biocel.2019.02.006","article-title":"STAT3beta, a distinct isoform from STAT3","volume":"110","author":"Zhang","year":"2019","journal-title":"Int J Biochem Cell Biol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"9214","DOI":"10.1038\/43213","article-title":"A new protein containing an SH2 domain that inhibits JAK kinases","volume":"387","author":"Endo","year":"1997","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","first-page":"27989","DOI":"10.1038\/nsmb.3378","article-title":"STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling","volume":"24","author":"Arimoto","year":"2017","journal-title":"Nat Struct Mol Biol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.immuni.2012.01.010","article-title":"JAK\u2019s SOCS: a mechanism of inhibition","volume":"36","author":"Yoshimura","year":"2012","journal-title":"Immunity"},{"key":"B60","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B61","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","article-title":"The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells","volume":"15","author":"Seif","year":"2017","journal-title":"Cell Commun Signal"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e20250003","DOI":"10.70962\/jhi.20250003","article-title":"Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee","volume":"1","author":"Poli","year":"2025","journal-title":"J Hum Immun"},{"key":"B63","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/377065a0","article-title":"Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)","volume":"377","author":"Macchi","year":"1995","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","first-page":"797800","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Science"},{"key":"B65","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41392-024-01934-w","article-title":"The JAK-STAT pathway: from structural biology to cytokine engineering","volume":"9","author":"Lv","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B66","doi-asserted-by":"publisher","first-page":"28196","DOI":"10.1007\/s10875-010-9489-z","article-title":"Molecular diagnosis of severe combined immunodeficiency\u2013identification of IL2RG, JAK3, IL7R, DCLRE1C, RAG1, and RAG2 mutations in a cohort of Chinese and Southeast Asian children","volume":"31","author":"Lee","year":"2011","journal-title":"J Clin Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"77883","DOI":"10.1007\/s10875-011-9564-0","article-title":"Severe combined immunodeficiency in Greek children over a 20-year period: rarity of \u03b3c-chain deficiency (X-linked) type","volume":"31","author":"Michos","year":"2011","journal-title":"J Clin Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1007\/s10875-014-9991-9","article-title":"Severe combined immunodeficiency in Serbia and Montenegro between years 1986 and 2010: a single-center experience","volume":"34","author":"Pasic","year":"2014","journal-title":"J Clin Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"14508","DOI":"10.1016\/j.jaci.2017.06.049","article-title":"Clinical, immunologic, and genetic spectrum of 696 patients with combined immunodeficiency","volume":"141","author":"Abolhassani","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"173749","DOI":"10.1182\/blood-2018-03-840702","article-title":"SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery","volume":"132","author":"Haddad","year":"2018","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00023","article-title":"Clinical, immunological, and molecular findings in 57 patients with severe combined immunodeficiency (SCID) from India","volume":"10","author":"Aluri","year":"2019","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"31623","DOI":"10.1007\/s10875-019-00610-x","article-title":"Clinical features and HSCT outcome for SCID in Turkey","volume":"39","author":"Ikinciogullari","year":"2019","journal-title":"J Clin Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.619146","article-title":"Clinical, immunological, and molecular features of severe combined immune deficiency: A multi-institutional experience from India","volume":"11","author":"Vignesh","year":"2020","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e13163","DOI":"10.1111\/sji.13163","article-title":"Severe combined immunodeficiencies: Expanding the mutation spectrum in Turkey and identification of 12 novel variants","volume":"95","author":"Aykut","year":"2022","journal-title":"Scand J Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"113645","DOI":"10.1016\/j.jaci.2012.12.667","article-title":"Hypomorphic Janus kinase 3 mutations result in a spectrum of immune defects, including partial maternal T-cell engraftment","volume":"131","author":"Cattaneo","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B76","first-page":"21820","article-title":"Common variable immunodeficiency or late-onset combined immunodeficiency: A new hypomorphic JAK3 patient and review of the literature","volume":"25","author":"Abolhassani","year":"2015","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"10135","DOI":"10.1016\/s0140-6736(66)90119-x","article-title":"Job\u2019s Syndrome. Recurrent, \u00ab cold \u00bb, staphylococcal abscesses","volume":"1","author":"Davis","year":"1966","journal-title":"Lancet Lond Engl"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1097\/MD.0b013e31825f95b9","article-title":"Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey","volume":"91","author":"Chandesris","year":"2012","journal-title":"Med (Baltimore)"},{"key":"B79","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1016\/j.coi.2014.01.015","article-title":"STAT3 is a central regulator of lymphocyte differentiation and function","volume":"28","author":"Kane","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"9152","DOI":"10.3390\/ijms21239152","article-title":"Staphylococcus aureus and hyper-igE syndrome","volume":"21","author":"Park","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B81","doi-asserted-by":"publisher","first-page":"44855","DOI":"10.1038\/mi.2011.5","article-title":"New mechanism of oral immunity to mucosal candidiasis in hyper-IgE syndrome","volume":"4","author":"Conti","year":"2011","journal-title":"Mucosal Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"138990","DOI":"10.1016\/j.jaci.2010.01.047","article-title":"Invasive fungal disease in autosomal-dominant hyper-IgE syndrome","volume":"125","author":"Vinh","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/j.jaip.2019.02.041","article-title":"Spectrum of pulmonary aspergillosis in hyper-igE syndrome with autosomal-dominant STAT3 deficiency","volume":"7","author":"Dur\u00e9ault","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B84","doi-asserted-by":"publisher","first-page":"15517","DOI":"10.1084\/jem.20080218","article-title":"Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3","volume":"205","author":"Ma","year":"2008","journal-title":"J Exp Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaci.2022.09.028","article-title":"A germline STAT6 gain-of-function variant is associated with early-onset allergies","volume":"151","author":"Suratannon","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.jaci.2022.12.802","article-title":"STAT6 gain-of-function variant exacerbates multiple allergic symptoms","volume":"151","author":"Takeuchi","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e20221755","DOI":"10.1016\/j.clim.2023.109364","article-title":"Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease","volume":"220","author":"Sharma","year":"2023","journal-title":"J Exp Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jaci.2023.01.023","article-title":"Severe allergic dysregulation due to a gain of function mutation in the transcription factor STAT6","volume":"152","author":"Baris","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"161122","DOI":"10.1007\/s10875-023-01530-7","article-title":"Autosomal dominant STAT6 gain of function causes severe atopy associated with lymphoma","volume":"43","author":"Minskaia","year":"2023","journal-title":"J Clin Immunol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"113947","DOI":"10.1056\/NEJMoa022926","article-title":"Growth hormone insensitivity associated with a STAT5b mutation","volume":"349","author":"Kofoed","year":"2003","journal-title":"N Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","first-page":"42606","DOI":"10.1210\/jc.2005-0515","article-title":"Severe growth hormone insensitivity resulting from total absence of signal transducer and activator of transcription 5b","volume":"90","author":"Hwa","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B92","doi-asserted-by":"publisher","first-page":"34825","DOI":"10.1210\/jc.2006-0368","article-title":"Clinical and biochemical characteristics of a male patient with a novel homozygous STAT5b mutation","volume":"91","author":"Vidarsdottir","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-2882","article-title":"Characterization of immunodeficiency in a patient with growth hormone insensitivity secondary to a novel STAT5b gene mutation","volume":"118","author":"Bernasconi","year":"2006","journal-title":"Pediatrics"},{"key":"B94","doi-asserted-by":"publisher","first-page":"21824","DOI":"10.1159\/000101334","article-title":"Growth hormone insensitivity and severe short stature in siblings: a novel mutation at the exon 13-intron 13 junction of the STAT5b gene","volume":"68","author":"Hwa","year":"2007","journal-title":"Horm Res"},{"key":"B95","doi-asserted-by":"publisher","first-page":"34955","DOI":"10.1530\/EJE-10-0272","article-title":"A novel STAT5B mutation causing GH insensitivity syndrome associated with hyperprolactinemia and immune dysfunction in two male siblings","volume":"163","author":"Pugliese-Pires","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2554","article-title":"A novel missense mutation in the SH2 domain of the STAT5B gene results in a transcriptionally inactive STAT5b associated with severe IGF-I deficiency, immune dysfunction, and lack of pulmonary disease","volume":"97","author":"Scaglia","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B97","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jaci.2018.08.032","article-title":"Signal transducer and activator of transcription 5B deficiency due to a novel missense mutation in the coiled-coil domain","volume":"143","author":"Acres","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"111799","DOI":"10.1016\/j.mce.2022.111799","article-title":"Atypical STAT5B deficiency, severe short stature and mild immunodeficiency associated with a novel homozygous STAT5B Variant","volume":"559","author":"Catli","year":"2023","journal-title":"Mol Cell Endocrinol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1025373","article-title":"STAT5b: A master regulator of key biological pathways","volume":"13","author":"Smith","year":"2022","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"436875","DOI":"10.1182\/blood-2006-11-055756","article-title":"Nonredundant roles for Stat5a\/b in directly regulating Foxp3","volume":"109","author":"Yao","year":"2007","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00234","article-title":"The STAT5b pathway defect and autoimmunity","volume":"3","author":"Kanai","year":"2012","journal-title":"Front Immunol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/s41467-018-04521-0","article-title":"Dominant-negative STAT5B mutations cause growth hormone insensitivity with short stature and mild immune dysregulation","volume":"9","author":"Klammt","year":"2018","journal-title":"Nat Commun"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/j.jaip.2019.02.018","article-title":"Clinical aspects of STAT3 gain-of-function germline mutations: A systematic review","volume":"7","author":"Fabre","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B104","doi-asserted-by":"publisher","first-page":"41221","DOI":"10.1016\/j.bj.2021.03.003","article-title":"Germline STAT3 gain-of-function mutations in primary immunodeficiency: Impact on the cellular and clinical phenotype","volume":"44","author":"Faletti","year":"2021","journal-title":"BioMed J"},{"key":"B105","doi-asserted-by":"publisher","first-page":"5919","DOI":"10.1182\/blood-2014-09-602763","article-title":"Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations","volume":"125","author":"Milner","year":"2015","journal-title":"Blood"},{"key":"B106","doi-asserted-by":"publisher","first-page":"16677","DOI":"10.1016\/j.mce.2018.01.016","article-title":"Partial growth hormone insensitivity and dysregulatory immune disease associated with de novo germline activating STAT3 mutations","volume":"473","author":"Guti\u00e9rrez","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1297301","DOI":"10.1016\/j.jaci.2019.11.042","article-title":"Erythropoiesis defect observed in STAT3 GOF patients with severe anemia","volume":"145","author":"Mauracher","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.jaci.2016.12.957","article-title":"JAK1 gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome","volume":"139","author":"Del Bel","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.737747","article-title":"Autoinflammatory keratinization disease with hepatitis and autism reveals roles for JAK1 kinase hyperactivity in autoinflammation","volume":"12","author":"Takeichi","year":"2021","journal-title":"Front Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"97283","DOI":"10.1016\/j.jaci.2023.06.004","article-title":"Successful treatment of JAK1-associated inflammatory disease","volume":"152","author":"Fayand","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"e20232387","DOI":"10.1084\/jem.20232387","article-title":"Individuals with JAK1 variants are affected by syndromic features encompassing autoimmunity, atopy, colitis, and dermatitis","volume":"221","author":"Horesh","year":"2024","journal-title":"J Exp Med"},{"key":"B112","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41586-020-2265-1","article-title":"Whole-genome sequencing of a sporadic primary immunodeficiency cohort","volume":"583","author":"Thaventhiran","year":"2020","journal-title":"Nature"},{"key":"B113","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1038\/s41467-020-18925-4","article-title":"Early-onset autoimmunity associated with SOCS1 haploinsufficiency","volume":"11","author":"Hadjadj","year":"2020","journal-title":"Nat Commun"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.jaci.2020.07.033","article-title":"Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1","volume":"146","author":"Lee","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"e391402","DOI":"10.1016\/S2665-9913(24)00348-5","article-title":"Clinical manifestations, disease penetrance, and treatment in individuals with SOCS1 insufficiency: a registry-based and population-based study","volume":"7","author":"Hadjadj","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1053\/j.gastro.2020.07.040","article-title":"Loss-of-function mutation in PTPN2 causes aberrant activation of JAK signaling via STAT and very early onset intestinal inflammation","volume":"159","author":"Parlato","year":"2020","journal-title":"Gastroenterology"},{"key":"B117","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s12041-023-01433-x","article-title":"A homozygous missense variant in PTPN2 with early-onset Crohn\u2019s disease, growth failure and dysmorphic features in an infant: a case report","volume":"102","author":"Awwad","year":"2023","journal-title":"J Genet"},{"key":"B118","doi-asserted-by":"publisher","first-page":"e20232337","DOI":"10.1084\/jem.20232337","article-title":"Haploinsufficiency in PTPN2 leads to early-onset systemic autoimmunity from Evans syndrome to lupus","volume":"221","author":"Jeanpierre","year":"2024","journal-title":"J Exp Med"},{"key":"B119","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1126\/science.1061154","article-title":"Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation","volume":"293","author":"Dupuis","year":"2001","journal-title":"Science"},{"key":"B120","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1371\/journal.pgen.0020131","article-title":"Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease","volume":"2","author":"Chapgier","year":"2006","journal-title":"PloS Genet"},{"key":"B121","doi-asserted-by":"publisher","first-page":"6819","DOI":"10.1007\/s10875-012-9659-2","article-title":"A novel stat1 mutation associated with disseminated mycobacterial disease","volume":"32","author":"Sampaio","year":"2012","journal-title":"J Clin Immunol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"137787","DOI":"10.1002\/humu.22113","article-title":"Dominant-negative STAT1 SH2 domain mutations in unrelated patients with Mendelian susceptibility to mycobacterial disease","volume":"33","author":"Tsumura","year":"2012","journal-title":"Hum Mutat"},{"key":"B123","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1016\/j.clim.2016.11.004","article-title":"A heterozygous dominant-negative mutation in the coiled-coil domain of STAT1 is the cause of autosomal-dominant Mendelian susceptibility to mycobacterial diseases","volume":"174","author":"Ueki","year":"2017","journal-title":"Clin Immunol Orlando Fla"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.bbrc.2021.11.036","article-title":"Two novel STAT1 mutations cause Mendelian susceptibility to mycobacterial disease","volume":"591","author":"Liu","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.1002140","article-title":"A novel STAT1 loss-of-function mutation associated with Mendelian susceptibility to mycobacterial disease","volume":"12","author":"Ye","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"177894","DOI":"10.1007\/s10875-022-01339-w","article-title":"Genetic and functional identifying of novel STAT1 loss-of-function mutations in patients with diverse clinical phenotypes","volume":"42","author":"Chen","year":"2022","journal-title":"J Clin Immunol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/s12887-023-04206-8","article-title":"A rare mutation causing autosomal dominant STAT1 deficiency in a South African multiplex kindred with disseminated BCG infection","volume":"23","author":"Greybe","year":"2023","journal-title":"BMC Pediatr"},{"key":"B128","doi-asserted-by":"publisher","first-page":"46678","DOI":"10.1007\/s10875-022-01396-1","article-title":"Novel STAT1 variants in Japanese patients with isolated mendelian susceptibility to mycobacterial diseases","volume":"43","author":"Ono","year":"2023","journal-title":"J Clin Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1595389","article-title":"A novel loss-of-function variant in STAT1 causes Mendelian susceptibility to mycobacterial disease","volume":"15","author":"Lv","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02061","article-title":"The dual nature of type I and type II interferons","volume":"9","author":"Lee","year":"2018","journal-title":"Front Immunol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"74555","DOI":"10.1016\/j.immuni.2006.09.009","article-title":"Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity","volume":"25","author":"Minegishi","year":"2006","journal-title":"Immunity"},{"key":"B132","doi-asserted-by":"publisher","first-page":"164162","DOI":"10.1084\/jem.20140280","article-title":"Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome","volume":"212","author":"Kreins","year":"2015","journal-title":"J Exp Med"},{"key":"B133","doi-asserted-by":"publisher","first-page":"696726","DOI":"10.1007\/s10875-015-0201-1","article-title":"Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency 2015","volume":"35","author":"Picard","year":"2015","journal-title":"J Clin Immunol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"e20220094","DOI":"10.1084\/jem.20220094","article-title":"Impaired IL-23-dependent induction of IFN-\u03b3 underlies mycobacterial disease in patients with inherited TYK2 deficiency","volume":"219","author":"Ogishi","year":"2022","journal-title":"J Exp Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00253","article-title":"A TYK2 gene mutation c.2395G>A leads to TYK2 deficiency: A case report and literature review","volume":"8","author":"Wu","year":"2020","journal-title":"Front Pediatr"},{"key":"B136","doi-asserted-by":"publisher","first-page":"e20220131","DOI":"10.1084\/jem.20220131","article-title":"Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia","volume":"219","author":"Zhang","year":"2022","journal-title":"J Exp Med"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aau8714","article-title":"Tuberculosis and impaired IL-23-dependent IFN-\u03b3 immunity in humans homozygous for a common TYK2 missense variant","volume":"3","author":"Boisson-Dupuis","year":"2018","journal-title":"Sci Immunol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"13992","DOI":"10.1038\/ncomms13992","article-title":"Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection","volume":"7","author":"Eletto","year":"2016","journal-title":"Nat Commun"},{"key":"B139","doi-asserted-by":"publisher","first-page":"38891","DOI":"10.1038\/ng1097","article-title":"Impaired response to interferon-alpha\/beta and lethal viral disease in human STAT1 deficiency","volume":"33","author":"Dupuis","year":"2003","journal-title":"Nat Genet"},{"key":"B140","doi-asserted-by":"publisher","first-page":"507883","DOI":"10.4049\/jimmunol.176.8.5078","article-title":"Human complete Stat-1 deficiency is associated with defective type I and II IFN responses in vitro but immunity to some low virulence viruses in vivo","volume":"176","author":"Chapgier","year":"2006","journal-title":"J Immunol Baltim Md 1950"},{"key":"B141","doi-asserted-by":"publisher","first-page":"180617","DOI":"10.1182\/blood-2011-01-330571","article-title":"Severe impairment of IFN-\u03b3 and IFN-\u03b1 responses in cells of a patient with a novel STAT1 splicing mutation","volume":"118","author":"Vairo","year":"2011","journal-title":"Blood"},{"key":"B142","doi-asserted-by":"publisher","first-page":"66371","DOI":"10.1093\/intimm\/dxaa043","article-title":"Autosomal recessive complete STAT1 deficiency caused by compound heterozygous intronic mutations","volume":"32","author":"Sakata","year":"2020","journal-title":"Int Immunol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"310211","DOI":"10.1016\/j.jaip.2020.06.034","article-title":"A novel complete autosomal-recessive STAT1 LOF variant causes immunodeficiency with hemophagocytic lymphohistiocytosis-like hyperinflammation","volume":"8","author":"Boehmer","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B144","doi-asserted-by":"publisher","first-page":"13352","DOI":"10.4049\/jimmunol.2001451","article-title":"Genetic, immunological, and clinical features of 32 patients with autosomal recessive STAT1 deficiency","volume":"207","author":"Le Voyer","year":"2021","journal-title":"J Immunol Baltim Md 1950"},{"key":"B145","doi-asserted-by":"publisher","first-page":"150214","DOI":"10.1172\/JCI37083","article-title":"A partial form of recessive STAT1 deficiency in humans","volume":"119","author":"Chapgier","year":"2009","journal-title":"J Clin Invest"},{"key":"B146","doi-asserted-by":"publisher","first-page":"5895906","DOI":"10.1182\/blood-2010-04-280586","article-title":"A novel form of human STAT1 deficiency impairing early but not late responses to interferons","volume":"116","author":"Kong","year":"2010","journal-title":"Blood"},{"key":"B147","doi-asserted-by":"publisher","first-page":"26571","DOI":"10.1007\/s10875-010-9480-8","article-title":"Novel STAT1 alleles in a patient with impaired resistance to mycobacteria","volume":"31","author":"Kristensen","year":"2011","journal-title":"J Clin Immunol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"7181","DOI":"10.1016\/j.cytogfr.2016.02.010","article-title":"The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses","volume":"29","author":"Blaszczyk","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"B149","doi-asserted-by":"publisher","first-page":"e168321","DOI":"10.1172\/JCI168321","article-title":"Human inherited complete STAT2 deficiency underlies inflammatory viral diseases","volume":"133","author":"Bucciol","year":"2023","journal-title":"J Clin Invest"},{"key":"B150","doi-asserted-by":"publisher","first-page":"315464","DOI":"10.1182\/blood-2015-11-679902","article-title":"Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype","volume":"127","author":"Toubiana","year":"2016","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","first-page":"283446","DOI":"10.1002\/eji.201445344","article-title":"Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC)","volume":"45","author":"Zheng","year":"2015","journal-title":"Eur J Immunol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"eaav7501","DOI":"10.1126\/sciimmunol.aav7501","article-title":"Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2","volume":"4","author":"Duncan","year":"2019","journal-title":"Sci Immunol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"80818","DOI":"10.1007\/s10875-023-01445-3","article-title":"Type I interferonopathy due to a homozygous loss-of-inhibitory function mutation in STAT2","volume":"43","author":"Zhu","year":"2023","journal-title":"J Clin Immunol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"e20192319","DOI":"10.1084\/jem.20192319","article-title":"Homozygous STAT2 gain-of-function mutation by loss of USP18 activity in a patient with type I interferonopathy","volume":"217","author":"Gruber","year":"2020","journal-title":"J Exp Med"},{"key":"B155","doi-asserted-by":"publisher","first-page":"224152","DOI":"10.1056\/NEJMoa2202318","article-title":"Variant STAT4 and response to ruxolitinib in an autoinflammatory syndrome","volume":"388","author":"Baghdassarian","year":"2023","journal-title":"N Engl J Med"},{"key":"B156","doi-asserted-by":"publisher","first-page":"454150","DOI":"10.1182\/blood-2012-12-474577","article-title":"Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia","volume":"121","author":"Rajala","year":"2013","journal-title":"Blood"},{"key":"B157","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1182\/blood-2016-09-737817","article-title":"Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea","volume":"129","author":"Ma","year":"2017","journal-title":"Blood"},{"key":"B158","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1007\/s10875-019-00737-x","article-title":"Human inborn errors of immunity: 2019 update on the classification from the international union of immunological societies expert committee","volume":"40","author":"Tangye","year":"2020","journal-title":"J Clin Immunol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.immuni.2020.07.006","article-title":"Complex autoinflammatory syndrome unveils fundamental principles of JAK1 kinase transcriptional and biochemical function","volume":"53","author":"Gruber","year":"2020","journal-title":"Immunity"},{"key":"B160","doi-asserted-by":"publisher","first-page":"293322","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00277-007-0403-6","article-title":"The diagnosis of BCR\/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers","volume":"87","author":"Haferlach","year":"2008","journal-title":"Ann Hematol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"190921","DOI":"10.1182\/blood.2022017578","article-title":"Genetic basis and molecular profiling in myeloproliferative neoplasms","volume":"141","author":"Luque Paz","year":"2023","journal-title":"Blood"},{"key":"B163","doi-asserted-by":"publisher","first-page":"38797","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"B164","doi-asserted-by":"publisher","first-page":"105461","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet Lond Engl"},{"key":"B165","doi-asserted-by":"publisher","first-page":"14346","DOI":"10.1038\/sj.onc.1209163","article-title":"The JAK2 V617F mutation in de novo acute myelogenous leukemias","volume":"25","author":"Lee","year":"2006","journal-title":"Oncogene"},{"key":"B166","doi-asserted-by":"publisher","first-page":"28136","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"key":"B167","doi-asserted-by":"publisher","first-page":"9839","DOI":"10.1007\/s00277-020-04004-7","article-title":"JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis","volume":"99","author":"Maddali","year":"2020","journal-title":"Ann Hematol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3978\/j.issn.2306-9759.2015.08.01","article-title":"Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs)","volume":"2","author":"Luo","year":"2015","journal-title":"Stem Cell Investig"},{"key":"B169","doi-asserted-by":"publisher","first-page":"499509","DOI":"10.1038\/s41375-019-0564-z","article-title":"Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface","volume":"34","author":"Masubuchi","year":"2020","journal-title":"Leukemia"},{"key":"B170","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41408-018-0159-3","article-title":"MPL-mutated essential thrombocythemia: a morphologic reappraisal","volume":"8","author":"Szuber","year":"2018","journal-title":"Blood Cancer J"},{"key":"B171","doi-asserted-by":"publisher","first-page":"812","DOI":"10.4274\/tjh.65807","article-title":"MPL W515L\/K mutations in chronic myeloproliferative neoplasms","volume":"30","author":"Akp\u0131nar","year":"2013","journal-title":"Turk J Haematol Off J Turk Soc Haematol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"283244","DOI":"10.1172\/JCI35808","article-title":"Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2","volume":"118","author":"Bersenev","year":"2008","journal-title":"J Clin Invest"},{"key":"B173","doi-asserted-by":"publisher","first-page":"24851","DOI":"10.1002\/ajh.24259","article-title":"LNK mutations and myeloproliferative disorders","volume":"91","author":"McMullin","year":"2016","journal-title":"Am J Hematol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"18695","DOI":"10.1016\/j.ijbiomac.2013.05.029","article-title":"The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability","volume":"60","author":"Li","year":"2013","journal-title":"Int J Biol Macromol"},{"key":"B175","doi-asserted-by":"publisher","first-page":"130912","DOI":"10.1126\/science.278.5341.1309","article-title":"A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia","volume":"278","author":"Lacronique","year":"1997","journal-title":"Science"},{"key":"B176","doi-asserted-by":"publisher","first-page":"75969","DOI":"10.1007\/s00277-013-1695-3","article-title":"Hematologic Malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1","volume":"92","author":"Patterer","year":"2013","journal-title":"Ann Hematol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.942053","article-title":"JAK2 alterations in acute lymphoblastic leukemia: molecular insights for superior precision medicine strategies","volume":"10","author":"Downes","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"16876","DOI":"10.1016\/j.coi.2010.02.004","article-title":"STAT5 in B cell development and leukemia","volume":"22","author":"Malin","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"13546","DOI":"10.1002\/gcc.22421","article-title":"Prognostic significance of P2RY8-CRLF2 and CRLF2 overexpression may vary across risk subgroups of childhood B-cell acute lymphoblastic leukemia","volume":"56","author":"Dou","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"B180","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.3390\/cancers11121952","article-title":"Deleterious and oncogenic mutations in the IL7RA","volume":"11","author":"Campos","year":"2019","journal-title":"Cancers"},{"key":"B181","doi-asserted-by":"publisher","first-page":"9018","DOI":"10.1084\/jem.201105802011512c","article-title":"Gain-of-function mutations in interleukin-7 receptor-\u03b1 (IL7R) in childhood acute lymphoblastic leukemias","volume":"208","author":"Shochat","year":"2011","journal-title":"J Exp Med"},{"key":"B182","doi-asserted-by":"publisher","first-page":"15763","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.104992","article-title":"The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse","volume":"99","author":"Bandapalli","year":"2014","journal-title":"Haematologica"},{"key":"B184","doi-asserted-by":"publisher","first-page":"11297","DOI":"10.3390\/ijms231911297","article-title":"Genomic mutations of the STAT5 transcription factor are associated with human cancer and immune diseases","volume":"23","author":"Kim","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B185","doi-asserted-by":"publisher","first-page":"9906","DOI":"10.5858\/2005-129-990-ASOTSP","article-title":"Activation status of the JAK\/STAT3 pathway in mantle cell lymphoma","volume":"129","author":"Yared","year":"2005","journal-title":"Arch Pathol Lab Med"},{"key":"B186","doi-asserted-by":"publisher","first-page":"245465","DOI":"10.1182\/blood-2017-11-814913","article-title":"Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma","volume":"131","author":"Tiacci","year":"2018","journal-title":"Blood"},{"key":"B187","doi-asserted-by":"publisher","first-page":"43547","DOI":"10.3324\/haematol.2019.216986","article-title":"High activation of STAT5A drives peripheral T-cell lymphoma and leukemia","volume":"105","author":"Maurer","year":"2020","journal-title":"Haematologica"},{"key":"B188","doi-asserted-by":"publisher","first-page":"190513","DOI":"10.1056\/NEJMoa1114885","article-title":"Somatic STAT3 mutations in large granular lymphocytic leukemia","volume":"366","author":"Koskela","year":"2012","journal-title":"N Engl J Med"},{"key":"B189","doi-asserted-by":"publisher","first-page":"53350","DOI":"10.1146\/annurev-immunol-110416-120628","article-title":"Disorders of the JAK\/STAT pathway in T cell lymphoma pathogenesis: implications for immunotherapy","volume":"35","author":"Waldmann","year":"2017","journal-title":"Annu Rev Immunol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"e4503","DOI":"10.3324\/haematol.2015.132837","article-title":"Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma","volume":"100","author":"P\u00e9rez","year":"2015","journal-title":"Haematologica"},{"key":"B191","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.2217\/ijh-2017-0002","article-title":"Understanding the molecular basis of acute myeloid leukemias: where are we now","volume":"6","author":"Gruszka","year":"2017","journal-title":"Int J Hematol Oncol"},{"key":"B192","doi-asserted-by":"publisher","first-page":"112838","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"B193","doi-asserted-by":"publisher","first-page":"61631","DOI":"10.1158\/2159-8290.CD-17-0583","article-title":"HOXA9 cooperates with activated JAK\/STAT signaling to drive leukemia development","volume":"8","author":"de Bock","year":"2018","journal-title":"Cancer Discov"},{"key":"B194","doi-asserted-by":"publisher","first-page":"40306","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"key":"B195","doi-asserted-by":"publisher","first-page":"145760","DOI":"10.1016\/j.leukres.2006.01.008","article-title":"JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia","volume":"30","author":"Mesa","year":"2006","journal-title":"Leuk Res"},{"key":"B196","doi-asserted-by":"publisher","first-page":"32933","DOI":"10.1002\/gcc.20235","article-title":"A BCR-JAK2 fusion gene as the result of a t(9,22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia","volume":"44","author":"Griesinger","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"B197","doi-asserted-by":"publisher","first-page":"3164\u221273","DOI":"10.1182\/blood-2002-06-1677","article-title":"Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations","volume":"101","author":"Mizuki","year":"2003","journal-title":"Blood"},{"key":"B198","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3390\/biomedicines9081051","article-title":"The ups and downs of STAT inhibition in acute myeloid leukemia","volume":"9","author":"Moser","year":"2021","journal-title":"Biomedicines"},{"key":"B199","doi-asserted-by":"publisher","first-page":"9023","DOI":"10.3390\/ijms25169023","article-title":"KMT2A rearrangements in leukemias: molecular aspects and therapeutic perspectives","volume":"25","author":"Guarnera","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B200","doi-asserted-by":"publisher","first-page":"99616","DOI":"10.7314\/APJCP.2014.15.22.9961","article-title":"Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias","volume":"15","author":"Ye","year":"2014","journal-title":"Asian Pac J Cancer Prev APJCP"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00367\/full","article-title":"Toll-like receptors and cancer: MYD88 mutation and inflammation","volume":"5","author":"Wang","year":"2014","journal-title":"Front Immunol"},{"key":"B202","doi-asserted-by":"publisher","first-page":"68698","DOI":"10.1182\/blood-2016-01-693879","article-title":"Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia","volume":"128","author":"Metzeler","year":"2016","journal-title":"Blood"},{"key":"B203","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1182\/blood-2006-05-024018","article-title":"Activation mechanisms of STAT5 by oncogenic Flt3-ITD","volume":"110","author":"Choudhary","year":"2007","journal-title":"Blood"},{"key":"B204","doi-asserted-by":"publisher","first-page":"16507","DOI":"10.1038\/onc.2014.109","article-title":"Phosphorylated STAT3 physically interacts with NPM and transcriptionally enhances its expression in cancer","volume":"34","author":"Ren","year":"2015","journal-title":"Oncogene"},{"key":"B205","doi-asserted-by":"publisher","first-page":"136709","DOI":"10.1073\/pnas.1918307117","article-title":"Combined inhibition of JAK\/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R\/CEBPA mutant acute myeloid leukemia","volume":"117","author":"Braun","year":"2020","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B206","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s40364-024-00676-9","article-title":"From regulation to deregulation of p53 in hematologic Malignancies: implications for diagnosis, prognosis and therapy","volume":"12","author":"Ahmadi","year":"2024","journal-title":"biomark Res"},{"key":"B207","doi-asserted-by":"publisher","first-page":"22134","DOI":"10.1016\/S0022-1759(03)00177-7","article-title":"Flow cytometric analysis of cytokine receptor signal transduction","volume":"278","author":"Ilangumaran","year":"2003","journal-title":"J Immunol Methods"},{"key":"B208","doi-asserted-by":"publisher","first-page":"311320","DOI":"10.4049\/jimmunol.142.9.3113","article-title":"Activation by IL-2, but not IL-4, up-regulates the expression of the p55 subunit of the IL-2 receptor on IL-2- and IL-4-dependent T cell lines","volume":"142","author":"Jankovic","year":"1989","journal-title":"J Immunol"},{"key":"B209","doi-asserted-by":"publisher","first-page":"667588","DOI":"10.1074\/jbc.M001748200","article-title":"DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites","volume":"276","author":"Ehret","year":"2001","journal-title":"J Biol Chem"},{"key":"B210","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.4161\/jkst.18006","article-title":"Modulation of human JAK-STAT pathway signaling by functionally conserved regulators","volume":"1","author":"M\u00fcller","year":"2012","journal-title":"JAK-STAT"},{"key":"B211","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1093\/nar\/gkp045","article-title":"Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data","volume":"37","author":"Ruijter","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"B212","doi-asserted-by":"publisher","first-page":"108545","DOI":"10.1016\/j.celrep.2020.108545","article-title":"CDK8 fine-tunes IL-6 transcriptional activities by limiting STAT3 resident time at the gene loci","volume":"33","author":"Martinez-Fabregas","year":"2020","journal-title":"Cell Rep"},{"key":"B213","doi-asserted-by":"publisher","first-page":"24355","DOI":"10.1016\/S0022-1759(00)00238-6","article-title":"Multiplexed particle-based flow cytometric assays","volume":"243","author":"Vignali","year":"2000","journal-title":"J Immunol Methods"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2014.04.006","article-title":"Validation of a multiplex electrochemiluminescent immunoassay platform in human and mouse samples","volume":"408","author":"Bastarache","year":"2014","journal-title":"J Immunol Methods"},{"key":"B215","doi-asserted-by":"publisher","first-page":"122737","DOI":"10.1016\/S0301-472X(02)00922-0","article-title":"Multiplexed microsphere-based flow cytometric assays","volume":"30","author":"Kellar","year":"2002","journal-title":"Exp Hematol"},{"key":"B216","doi-asserted-by":"publisher","first-page":"87984","DOI":"10.1093\/gerona\/63.8.879","article-title":"ELISA and multiplex technologies for cytokine measurement in inflammation and aging research","volume":"63","author":"Leng","year":"2008","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"B217","doi-asserted-by":"publisher","first-page":"14552","DOI":"10.1016\/j.cyto.2016.12.021","article-title":"Comparison of multiplex platforms for cytokine assessments and their potential use for biomarker profiling in multiple sclerosis","volume":"91","author":"Malekzadeh","year":"2017","journal-title":"Cytokine"},{"key":"B218","doi-asserted-by":"publisher","first-page":"11933","DOI":"10.1007\/978-1-60327-527-9_9","article-title":"Cytokine multiplex immunoassay: methodology and (clinical) applications","volume":"514","author":"de Jager","year":"2009","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"B219","doi-asserted-by":"publisher","first-page":"67784","DOI":"10.31557\/APJCP.2025.26.2.677","article-title":"Frequency of JAK2V617F mutation zygosity and impact on disease outcome in MPN patients","volume":"26","author":"Khazeem","year":"2025","journal-title":"Asian Pac J Cancer Prev APJCP"},{"key":"B220","doi-asserted-by":"publisher","first-page":"195200","DOI":"10.1182\/asheducation-2005.1.195","article-title":"A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases","volume":"2005","author":"Vainchenker","year":"2005","journal-title":"Hematology"},{"key":"B221","first-page":"1129","article-title":"JAK2 V617F: A single mutation in the myeloproliferative group of disorders","volume":"75","author":"McLornan","year":"2006","journal-title":"Ulster Med J"},{"key":"B222","doi-asserted-by":"publisher","first-page":"194553","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet Lond Engl"},{"key":"B223","doi-asserted-by":"publisher","first-page":"71321","DOI":"10.1309\/AJCPFHUQZ9AGUEKA","article-title":"Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods","volume":"132","author":"Cankovic","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"B224","doi-asserted-by":"publisher","first-page":"10511","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"key":"B225","doi-asserted-by":"publisher","first-page":"237990","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"B226","doi-asserted-by":"publisher","first-page":"45968","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2Exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"B227","doi-asserted-by":"publisher","first-page":"25678","DOI":"10.1093\/bib\/bbs086","article-title":"A survey of tools for variant analysis of next-generation genome sequencing data","volume":"15","author":"Pabinger","year":"2014","journal-title":"Brief Bioinform"},{"key":"B228","doi-asserted-by":"publisher","first-page":"73347","DOI":"10.1038\/gim.2013.92","article-title":"ACMG clinical laboratory standards for next-generation sequencing","volume":"15","author":"Rehm","year":"2013","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"B229","doi-asserted-by":"publisher","first-page":"895906","DOI":"10.1016\/j.ajhg.2017.04.015","article-title":"Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the clinical genome resource","volume":"100","author":"Strande","year":"2017","journal-title":"Am J Hum Genet"},{"key":"B230","doi-asserted-by":"publisher","first-page":"52934","DOI":"10.1016\/j.jaci.2013.08.032","article-title":"Targeted next-generation sequencing: a novel diagnostic tool for primary immunodeficiencies","volume":"133","author":"Nijman","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00466\/full","article-title":"Diagnostics of primary immunodeficiencies through next-generation sequencing","volume":"7","author":"Gallo","year":"2016","journal-title":"Front Immunol"},{"key":"B232","doi-asserted-by":"publisher","first-page":"68398","DOI":"10.1038\/s41584-024-01168-8","article-title":"Somatic mutations in autoinflammatory and autoimmune disease","volume":"20","author":"Torreggiani","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B233","doi-asserted-by":"publisher","first-page":"82","DOI":"10.12688\/f1000research.13167.1","article-title":"JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders","volume":"7","author":"Vainchenker","year":"2018","journal-title":"F1000Research"},{"key":"B234","doi-asserted-by":"publisher","first-page":"798809","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B235","doi-asserted-by":"publisher","first-page":"21908","DOI":"10.1182\/blood-2008-03-077966","article-title":"Myeloproliferative disorders","volume":"112","author":"Levine","year":"2008","journal-title":"Blood"},{"key":"B236","doi-asserted-by":"publisher","first-page":"193340","DOI":"10.1158\/1078-0432.CCR-12-0284","article-title":"Molecular pathways: Jak\/STAT pathway: mutations, inhibitors, and resistance","volume":"19","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B237","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1038\/nature08250","article-title":"Targeted capture and massively parallel sequencing of 12 human exomes","volume":"461","author":"Ng","year":"2009","journal-title":"Nature"},{"key":"B238","doi-asserted-by":"publisher","first-page":"43443","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"B239","doi-asserted-by":"publisher","first-page":"66577","DOI":"10.1007\/s00439-017-1779-6","article-title":"The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies","volume":"136","author":"Stenson","year":"2017","journal-title":"Hum Genet"},{"key":"B240","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/gm432","article-title":"Low concordance of multiple variant-calling pipelines: practical implications for exome and genome sequencing","volume":"5","author":"O\u2019Rawe","year":"2013","journal-title":"Genome Med"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1038\/npjgenmed.2015.12","article-title":"Whole genome sequencing expands diagnostic utility and improves clinical management in pediatric medicine","volume":"1","author":"Stavropoulos","year":"2016","journal-title":"NPJ Genomic Med"},{"key":"B242","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.1038\/nature25983","article-title":"De novo mutations in regulatory elements in neurodevelopmental disorders","volume":"555","author":"Short","year":"2018","journal-title":"Nature"},{"key":"B243","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1038\/nature13394","article-title":"Genome sequencing identifies major causes of severe intellectual disability","volume":"511","author":"Gilissen","year":"2014","journal-title":"Nature"},{"key":"B244","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41525-024-00391-2","article-title":"Whole genome sequencing enables new genetic diagnosis for inherited retinal diseases by identifying pathogenic variants","volume":"9","author":"Liu","year":"2024","journal-title":"NPJ Genomic Med"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00426\/full","article-title":"Long-read sequencing emerging in medical genetics","volume":"10","author":"Mantere","year":"2019","journal-title":"Front Genet"},{"key":"B246","doi-asserted-by":"publisher","first-page":"57484","DOI":"10.1097\/GIM.0b013e318145b25b","article-title":"Detection of DNA copy number alterations in cancer by array comparative genomic hybridization","volume":"9","author":"Michels","year":"2007","journal-title":"Genet Med"},{"key":"B247","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1038\/ng0501-29","article-title":"SOCS-1, a negative regulator of the JAK\/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity","volume":"28","author":"Yoshikawa","year":"2001","journal-title":"Nat Genet"},{"key":"B248","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.3390\/cancers13164000","article-title":"The emerging role of suppressors of cytokine signaling (SOCS) in the development and progression of leukemia","volume":"13","author":"Keewan","year":"2021","journal-title":"Cancers"},{"key":"B249","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.immuni.2020.09.008","article-title":"Rapid enhancer remodeling and transcription factor repurposing enable high magnitude gene induction upon acute activation of NK cells","volume":"53","author":"Scium\u00e8","year":"2020","journal-title":"Immunity"},{"key":"B250","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/978-1-4939-2772-2_7","article-title":"Luciferase reporter assays to study transcriptional activity of hedgehog signaling in normal and cancer cells","volume":"1322","author":"Pandolfi","year":"2015","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"B251","doi-asserted-by":"publisher","first-page":"16389","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-gamma: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J Leukoc Biol"},{"key":"B252","doi-asserted-by":"publisher","first-page":"773641","DOI":"10.1158\/0008-5472.CAN-08-1125","article-title":"Activation of signal transducer and activator of transcription 3 through a phosphomimetic serine 727 promotes prostate tumorigenesis independent of tyrosine 705 phosphorylation","volume":"68","author":"Qin","year":"2008","journal-title":"Cancer Res"},{"key":"B253","doi-asserted-by":"publisher","first-page":"4948","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"B254","doi-asserted-by":"publisher","first-page":"e6529","DOI":"10.1371\/journal.pone.0006529","article-title":"A versatile viral system for expression and depletion of proteins in mammalian cells","volume":"4","author":"Campeau","year":"2009","journal-title":"PloS One"},{"key":"B255","doi-asserted-by":"publisher","first-page":"16535","DOI":"10.1126\/science.1071545","article-title":"A road map for those who don\u2019t know JAK-STAT","volume":"296","author":"Aaronson","year":"2002","journal-title":"Science"},{"key":"B256","doi-asserted-by":"publisher","first-page":"90011","DOI":"10.1038\/nri1226","article-title":"Regulation of JAK-STAT signalling in the immune system","volume":"3","author":"Shuai","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B257","doi-asserted-by":"publisher","first-page":"295303","DOI":"10.1016\/S0092-8674(00)81959-5","article-title":"Stat3 as an oncogene","volume":"98","author":"Bromberg","year":"1999","journal-title":"Cell"},{"key":"B258","doi-asserted-by":"publisher","first-page":"37484","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak\u2013STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.770077","article-title":"STAT3 gain-of-function syndrome","volume":"10","author":"Vogel","year":"2022","journal-title":"Front Pediatr"},{"key":"B260","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/bs.mcb.2018.08.001","article-title":"Luciferase reporter assay for unlocking ligand-mediated signaling of GPCRs","volume":"149","author":"Unal","year":"2019","journal-title":"Methods Cell Biol"},{"key":"B261","doi-asserted-by":"publisher","first-page":"15768","DOI":"10.1002\/jcp.10364","article-title":"STAT proteins: from normal control of cellular events to tumorigenesis","volume":"197","author":"Cal\u00f2","year":"2003","journal-title":"J Cell Physiol"},{"key":"B262","doi-asserted-by":"publisher","first-page":"8048","DOI":"10.1038\/s41467-023-43790-2","article-title":"Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening","volume":"14","author":"Ramos","year":"2023","journal-title":"Nat Commun"},{"key":"B263","doi-asserted-by":"publisher","first-page":"53742","DOI":"10.1038\/nature23477","article-title":"Identification of essential genes for cancer immunotherapy","volume":"548","author":"Patel","year":"2017","journal-title":"Nature"},{"key":"B264","doi-asserted-by":"publisher","first-page":"54250","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O\u2019Shea","year":"2012","journal-title":"Immunity"},{"key":"B265","doi-asserted-by":"publisher","first-page":"50314","DOI":"10.1016\/j.immuni.2012.03.013","article-title":"The JAK-STAT pathway at twenty","volume":"36","author":"Stark","year":"2012","journal-title":"Immunity"},{"key":"B266","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1126\/science.1247005","article-title":"Genome-scale CRISPR-cas9 knockout screening in human cells","volume":"343","author":"Shalem","year":"2014","journal-title":"Science"},{"key":"B267","doi-asserted-by":"publisher","first-page":"81923","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"B268","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting STAT3 in cancer immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Mol Cancer"},{"key":"B269","doi-asserted-by":"publisher","first-page":"23041","DOI":"10.1016\/j.omtn.2017.09.009","article-title":"CRISPR\/cas9 genome-editing system in human stem cells: current status and future prospects","volume":"9","author":"Zhang","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"B270","doi-asserted-by":"publisher","first-page":"15804","DOI":"10.1136\/ard.2008.092866","article-title":"Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study","volume":"68","author":"Nishimoto","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B271","doi-asserted-by":"publisher","first-page":"799807","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"B272","doi-asserted-by":"publisher","first-page":"253540","DOI":"10.1182\/blood.V90.7.2535","article-title":"Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9,12) in a lymphoid and t(9,15,12) in a myeloid leukemia","volume":"90","author":"Peeters","year":"1997","journal-title":"Blood"},{"key":"B273","doi-asserted-by":"publisher","first-page":"724852","DOI":"10.1038\/sj.onc.1208850","article-title":"The t(8,9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene","volume":"24","author":"Bousquet","year":"2005","journal-title":"Oncogene"},{"key":"B274","doi-asserted-by":"publisher","first-page":"11448","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"B275","doi-asserted-by":"publisher","first-page":"160819","DOI":"10.1056\/NEJMoa073687","article-title":"STAT3 mutations in the hyper-IgE syndrome","volume":"357","author":"Holland","year":"2007","journal-title":"N Engl J Med"},{"key":"B276","doi-asserted-by":"publisher","first-page":"105862","DOI":"10.1038\/nature06096","article-title":"Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome","volume":"448","author":"Minegishi","year":"2007","journal-title":"Nature"},{"key":"B277","doi-asserted-by":"publisher","first-page":"16170","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O\u2019Shea","year":"2013","journal-title":"N Engl J Med"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.696350","article-title":"Case report: interleukin-2 receptor common gamma chain defect presented as a hyper-igE syndrome","volume":"12","author":"Belaid","year":"2021","journal-title":"Front Immunol"},{"key":"B279","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1126\/science.270.5237.800","article-title":"Defective lymphoid development in mice lacking Jak3","volume":"270","author":"Nosaka","year":"1995","journal-title":"Science"},{"key":"B280","doi-asserted-by":"publisher","first-page":"14757","DOI":"10.1016\/0092-8674(93)90167-O","article-title":"Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans","volume":"73","author":"Noguchi","year":"1993","journal-title":"Cell"},{"key":"B281","doi-asserted-by":"publisher","first-page":"80316","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"B282","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jaci.2023.10.018","article-title":"JAK inhibitor treatment for inborn errors of JAK\/STAT signaling: An ESID\/EBMT-IEWP retrospective study","volume":"153","author":"Fischer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B283","doi-asserted-by":"publisher","first-page":"e35661","DOI":"10.1002\/cncr.35661","article-title":"Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety","volume":"131","author":"Masarova","year":"2025","journal-title":"Cancer"},{"key":"B284","doi-asserted-by":"publisher","first-page":"55971","DOI":"10.1007\/s40262-023-01225-7","article-title":"Pharmacokinetics and pharmacodynamics of ruxolitinib: A review","volume":"62","author":"Appeldoorn","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"B285","article-title":"Tofacitinib","volume-title":"StatPearls [Internet]","author":"Padda","year":"2023"},{"key":"B286","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11926-020-00931-6","article-title":"JAK inhibitors: what is new","volume":"22","author":"Reddy","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"B287","doi-asserted-by":"publisher","first-page":"14352","DOI":"10.1080\/25785826.2023.2172808","article-title":"JAK inhibitors in rheumatology","volume":"46","author":"Yamaoka","year":"2023","journal-title":"Immunol Med"},{"key":"B288","doi-asserted-by":"publisher","first-page":"491060","DOI":"10.1007\/s12325-022-02281-4","article-title":"A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19","volume":"39","author":"Bieber","year":"2022","journal-title":"Adv Ther"},{"key":"B289","doi-asserted-by":"publisher","first-page":"e13688","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: Mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B290","doi-asserted-by":"publisher","first-page":"81932","DOI":"10.1007\/s40262-022-01129-y","article-title":"Filgotinib: A clinical pharmacology review","volume":"61","author":"Namour","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"B291","doi-asserted-by":"publisher","first-page":"167786","DOI":"10.1080\/14656566.2022.2135989","article-title":"Fedratinib: a pharmacotherapeutic option for JAK-inhibitor na\u00efve and exposed patients with myelofibrosis","volume":"23","author":"England","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"B292","doi-asserted-by":"publisher","DOI":"10.1177\/10600280231153863","article-title":"Deucravacitinib: the first FDA-approved oral TYK2 inhibitor for moderate to severe plaque psoriasis","volume":"58","author":"Tm","year":"2024","journal-title":"Ann Pharmacother"},{"key":"B293","doi-asserted-by":"publisher","first-page":"729\u221249","DOI":"10.1007\/s13555-023-00892-5","article-title":"A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol Ther"},{"key":"B294","doi-asserted-by":"publisher","first-page":"2653\u221268","DOI":"10.1007\/s13555-024-01243-8","article-title":"Practical recommendations on laboratory monitoring in patients with atopic dermatitis on oral JAK inhibitors","volume":"14","author":"Kirchhof","year":"2024","journal-title":"Dermatol Ther"},{"key":"B295","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.614704","article-title":"Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis","volume":"12","author":"Keenan","year":"2021","journal-title":"Front Immunol"},{"key":"B296","doi-asserted-by":"publisher","first-page":"489\u2212507","DOI":"10.1080\/00325481.2020.1855921","article-title":"JAK-STAT pathway inhibition and their implications in COVID-19 therapy","volume":"133","author":"Satarker","year":"2021","journal-title":"Postgrad Med"},{"key":"B297","doi-asserted-by":"publisher","first-page":"27","DOI":"10.20517\/2394-4722.2020.58","article-title":"Targeting the JAK\/STAT pathway in solid tumors","volume":"6","author":"Qureshy","year":"2020","journal-title":"J Cancer Metastasis Treat"},{"key":"B298","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.821344","article-title":"JAK\/STAT signaling: molecular targets, therapeutic opportunities, and limitations of targeted inhibitions in solid Malignancies","volume":"13","author":"Rah","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1669688\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:29:41Z","timestamp":1765175381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1669688\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":298,"alternative-id":["10.3389\/fimmu.2025.1669688"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1669688","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"article-number":"1669688"}}